PMID- 36483226
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221210
IS  - 2036-7392 (Print)
IS  - 2036-7406 (Electronic)
IS  - 2036-7392 (Linking)
VI  - 14
IP  - 4
DP  - 2022 Nov 21
TI  - Real-world treatment patterns, patient-reported outcomes, and effectiveness of 
      flexibledosing etanercept in patients with plaque psoriasis in Greece.
PG  - 9265
LID - 10.4081/dr.2022.9265 [doi]
LID - 9265
AB  - Etanercept is approved for continuous or intermittent use and flexible dosing in 
      plaque psoriasis (PsO). The objectives of this study were to investigate 
      real-world treatment patterns with etanercept in Greek adults with 
      moderate-to-severe PsO. This non-interventional multicenter study included a 
      retrospective-to-prospective (RP) cohort, previously treated with etanercept for 
      >/=24 months and followed for an additional 6 months, and a biologic-naive, 
      prospective-only (PO) cohort, followed for 6 months after treatment initiation. 
      Parameters assessed included Psoriasis Area and Severity Index (PASI), percentage 
      of body surface area (BSA) affected, Dermatology Life Quality Index (DLQI), and 
      adverse events (AEs). This study enrolled 123 patients (RP, n = 56; PO, n = 67), 
      who mostly adhered to continuous treatment (RP, 68%; PO, 95%). The two cohorts 
      had similar mean baseline-to-endpoint decreases in PASI (-9.5 vs -10.1) and BSA 
      (-11.9 vs -12.3). The PO-CTP population had a mean DLQI baseline-to-endpoint 
      score decrease of -5.8, which was statistically significant and clinically 
      meaningful. Treatment-emergent AE rates were 58.9% (RP) versus 26.9% (PO). These 
      real-world data suggest a similar effectiveness of continuous and intermittent 
      etanercept treatment in Greek patients with PsO.
CI  - (c)Copyright: the Author(s).
FAU - Rigopoulos, Dimitris
AU  - Rigopoulos D
AD  - University of Athens Medical School, Athens, Greece.
FAU - Patsatsi, Aikaterini
AU  - Patsatsi A
AD  - Papageorgiou General Hospital, Thessaloniki, Greece.
FAU - Antoniou, Christina
AU  - Antoniou C
AD  - University of Athens Medical School, Athens, Greece.
FAU - Sotiriadis, Dimitrios
AU  - Sotiriadis D
AD  - Aristotle University of Thessaloniki, Thessaloniki, Greece.
FAU - Schulze, Angeliki Roussaki-
AU  - Schulze AR
AD  - University of Thessaly and University Hospital of Larissa, Larissa, Greece.
FAU - Boubouchairopoulou, Nadia
AU  - Boubouchairopoulou N
AD  - Pfizer Hellas, Athens, Greece.
FAU - Skiadas, Ioannis
AU  - Skiadas I
AD  - Pfizer Hellas, Athens, Greece.
FAU - Tsekouras, Vasillios
AU  - Tsekouras V
AD  - Pfizer Hellas, Cyprus Branch, Nicosia, Cyprus.
FAU - Hernandez Daly, Ana Cristina
AU  - Hernandez Daly AC
AD  - Pfizer Hellas, Athens, Greece.
LA  - eng
PT  - Journal Article
DEP - 20221121
PL  - Italy
TA  - Dermatol Reports
JT  - Dermatology reports
JID - 101566470
PMC - PMC9724636
OTO - NOTNLM
OT  - Etanercept
OT  - Greece
OT  - psoriasis
OT  - real-world evidence
EDAT- 2022/12/10 06:00
MHDA- 2022/12/10 06:01
PMCR- 2022/11/21
CRDT- 2022/12/09 03:58
PHST- 2021/05/14 00:00 [received]
PHST- 2022/01/11 00:00 [accepted]
PHST- 2022/12/09 03:58 [entrez]
PHST- 2022/12/10 06:00 [pubmed]
PHST- 2022/12/10 06:01 [medline]
PHST- 2022/11/21 00:00 [pmc-release]
AID - 10.4081/dr.2022.9265 [doi]
PST - epublish
SO  - Dermatol Reports. 2022 Nov 21;14(4):9265. doi: 10.4081/dr.2022.9265. eCollection 
      2022 Nov 21.